By coating the implant in
the antibiotic microspheres before placing it in the patient's joint, the antibiotics are delivered directly to the surgical site to help prevent bacteria from developing into an infection.
He is currently seeking FDA approval of
the antibiotic microspheres and estimates they will be in use in three to eight years.
This is the third in a series of research studies lead investigator Catherine Ambrose, Ph.D., associate professor in the Department of Orthopaedic Surgery at the UTHealth Medical School, and collaborators have published that demonstrate the potential of
antibiotic microspheres.
Not exact matches
Made of biodegradable polymers, the
antibiotics are gradually released over a period of weeks and eventually the
microspheres dissolve, allowing sufficient time to prevent or treat an infection while reducing the likelihood of additional surgeries.
If future clinical studies show comparable findings in patients, Terry Clyburn, M.D., professor of orthopaedics and director of Total Joint Services at the UTHealth Medical School, said
antibiotic - containing
microspheres could serve to prevent these rare but devastating and often hard - to - treat infections.
The
microspheres could be administered directly at the surgical site, eliminating the need for systemic
antibiotics that impact the entire body.